In a pi­o­neer­ing first, As­traZeneca scores FDA OK to use its PARP against breast can­cer

As­traZeneca $AZN has picked up an­oth­er key win for its can­cer drug fran­chise.

The FDA ap­proved its PARP in­hibitor Lyn­parza for BR­CA-mu­tat­ed metasta­t­ic breast can­cer, of­fer­ing the phar­ma gi­ant a path for­ward to ex­pand its use be­yond ovar­i­an can­cer. And this is a first in the field.

Their Phase III da­ta made the show­case round at AS­CO last sum­mer and is fur­ther en­hanc­ing the FDA’s fo­cus on drugs that can tar­get can­cers trig­gered by the same ge­net­ic caus­es. The drug was linked with tu­mor shrink­age in 60% of the pa­tients with germline BR­CA1 or BR­CA2 mu­ta­tions tak­ing the drug, com­pared to 29% in the chemo group. And the OK gives them an edge over their ri­vals: Clo­vis’ Rubra­ca and Tesaro’s Ze­ju­la.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.